| 10.25 0.005 (0.05%) | 02-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.18 | 1-year : | 14.23 |
| Resists | First : | 10.43 | Second : | 12.18 |
| Pivot price | 10.24  |
|||
| Supports | First : | 10.12 | Second : | 9.94 |
| MAs | MA(5) : | 10.21  |
MA(20) : | 10.21 |
| MA(100) : | 6.53 |
MA(250) : | 4.42 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 45.8 |
D(3) : | 38.6 |
| RSI | RSI(14): 68.1 | |||
| 52-week | High : | 10.43 | Low : | 1.39 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GRCL ] has closed below upper band by 46.0%. Bollinger Bands are 88.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.26 - 10.32 | 10.32 - 10.37 |
| Low: | 10.11 - 10.18 | 10.18 - 10.24 |
| Close: | 10.16 - 10.26 | 10.26 - 10.35 |
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.
Thu, 22 Feb 2024
Gracell Biotechnologies Acquisition Completed - Yahoo Finance
Wed, 21 Feb 2024
AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR) - Seeking Alpha
Tue, 20 Feb 2024
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement - GlobeNewswire
Fri, 05 Jan 2024
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs - Bamboo Works
Wed, 27 Dec 2023
Why AstraZeneca’s Gracell Biotechnologies Acquisition Is A Win-Win (NASDAQ:GRCL) - Seeking Alpha
Wed, 27 Dec 2023
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 165 (M) |
| Held by Insiders | 16.3 (%) |
| Held by Institutions | 63.1 (%) |
| Shares Short | 1,190 (K) |
| Shares Short P.Month | 554 (K) |
| EPS | -0.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.89 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.5 % |
| Return on Equity (ttm) | -31.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -10.57 |
| PEG Ratio | 0 |
| Price to Book value | 0.6 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|